1. Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
- Author
-
Gatti-Mays, Margaret and Gulley, James L
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Immune checkpoint inhibitors ,medicine.medical_treatment ,Immunology ,programmed cell death 1 receptor ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,polycyclic compounds ,medicine ,Immunology and Allergy ,Adverse effect ,RC254-282 ,Pneumonitis ,Pharmacology ,business.industry ,Incidence (epidemiology) ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Immunotherapy ,Programmed Cell Death 1 Receptor ,medicine.disease ,Clinical trial ,Editorial ,030104 developmental biology ,030220 oncology & carcinogenesis ,Molecular Medicine ,immunotherapy ,Steroid refractory ,business ,guidelines as topic ,hormones, hormone substitutes, and hormone antagonists - Abstract
Immune checkpoint inhibitor (ICI)-induced pneumonitis has been considered a rare immune-related adverse event (irAE). Incidence is estimated at less than 5% of clinical trial patients, with high-grade pneumonitis occurring in less than 1% of patients who receive ICIs.[1 2][1] However, as ICIs gain
- Published
- 2021